title: [Ponatinib: new option for the treatment of resistant chronic myeloid leukemia].
authors.forename: Cristina
authors.initials: C
authors.lastname: Camañas-Troyano
authors.forename: Cristina
authors.initials: C
authors.lastname: Calderón-Acedos
authors.forename: María Del Carmen
authors.initials: Mdel C
authors.lastname: Moriel-Sánchez
authors.forename: María
authors.initials: M
authors.lastname: Segura-Bedmar
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001549:Benzamides / Q000494:pharmacology / Q000627:therapeutic use; D001752:Blast Crisis / Q000188:drug therapy*; D000069439:Dasatinib; D018450:Disease Progression; D017277:Drug Approval; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D057915:Drug Substitution; D005260:Female; D016044:Fusion Proteins, bcr-abl / Q000037:antagonists & inhibitors* / Q000235:genetics; D006801:Humans; D000068877:Imatinib Mesylate; D007093:Imidazoles / Q000009:adverse effects / Q000627:therapeutic use*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D008875:Middle Aged; D020125:Mutation, Missense; D010879:Piperazines / Q000494:pharmacology / Q000627:therapeutic use; D017354:Point Mutation; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011724:Pyridazines / Q000009:adverse effects / Q000627:therapeutic use*; D011743:Pyrimidines / Q000494:pharmacology / Q000627:therapeutic use; D013844:Thiazoles / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D007093:Imidazoles; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011724:Pyridazines; D011743:Pyrimidines; D013844:Thiazoles; C545373:ponatinib; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl; D000069439:Dasatinib